Filana Therapeutics, Inc. Common Stock (FLNA) Stock
NYSE · FLNA
Key stats
- Market cap
- $24.25M
- Price / Earnings ratio
- -0.6x
- EPS (TTM)
- -$0.87
- Volume
- Loading
- 52-week high
- $3.45
- 52-week low
- $0.43
Source: third-party data provider, as of November 13, 2026
Compare with FLNA
Technical indicators
- RSI 14
- 32.12
- MACD 12/26/9
- -0.08
- EMA 9 of MACD
- -0.07
- MACD histogram
- -0.01
- SMA 50
- $0.73
- Price below SMA 50
- EMA 50
- $0.72
- Price below EMA 50
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
No analyst data available
Financials
Performance
Revenue
Net income
Net margin %
2021
2022
2023
2024
2025
0000
Debt & Balance Sheet
Total assets
Total liabilities
2021
2022
2023
2024
2025
320M211M106M0
Revenue to Profit
2025$0.0
Revenue$0.0
Cost of revenue$0.0
Gross profit$0.0
Operating expenses$-91.0M
Net incomeEarnings
No data available
Source: third-party data provider
About Filana Therapeutics, Inc. Common Stock
No description available.
SectorHealthcare
IndustryBiotechnology
Employees17
CEOMr. Richard Jon Barry
IPO DateJul 14, 2000
HeadquartersAustin, TX
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Richard Jon Barry | CEO, President & Director | 1959 |
| Mr. Eric J. Schoen | Chief Financial Officer | 1968 |
| Mr. R. Christopher Cook J.D. | Chief Operating & Legal Officer | 1964 |
| Dr. George Thornton Ph.D. | Senior Vice President of Technology | — |
| Mr. Michael Zamloot | Senior Vice President of Technical Operations | — |
| Jaren Landen | Chief Clinical Development Officer | — |
| Dr. Angelique Bordey Ph.D. | Senior Vice President of Neuroscience | — |
| Mr. Jack Moore Ph.D. | Senior Vice President of Clinical Development | — |
| Dr. Joseph Hulihan M.D. | Chief Medical Officer | 1956 |
| Ms. Nancy Teasdale | Head of Regulatory Affairs | — |
Fundamentals
Valuation
Price-to-book value0.42
PEG ratio1.62
Profitability
Return on Equity-64.00%
Return on Assets-39.00%
EBITDA$-41.13M
Trading
Average volume376,987
Dividend
Ex dividend date13 Dec 2012
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 32.12
- MACD 12/26/9
- -0.08
- EMA 9 of MACD
- -0.07
- MACD histogram
- -0.01
- SMA 50
- $0.73
- Price below SMA 50
- EMA 50
- $0.72
- Price below EMA 50
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
No analyst data available
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -19.1 | -15.7 | +2.0 | -20.1 | -19.2 | -12.6 | +3.5 | -36.1 | -14.3 |
Compare stocks
Market cap
$24.25M
-
-
-
Price / Earnings ratio
-0.60
-
-
-
Price / Sales ratio
-
-
-
Dividend yield
0.00%
-
-
-
Average volume
376,987
-
-
-
Earnings per share
$-0.87
-
-
-




